Меню
Набор скоро начнётся NCT07434115

Orthobiological Therapies in Musculoskeletal Disorders

Ранняя фаза I С лечением Musculoskeletal Diseases or Conditions

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: PRP injection, Bone Marrow Concentrate (BMAC), Hyaluronic Acid (Viscosupplementation), Nanofat.
Кому может быть актуально
Состояния в реестре: Musculoskeletal Diseases or Conditions. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Clinical and Functional Evaluation of Orthobiological Therapies in Musculoskeletal Conditions

Обзор

To evaluate the clinical and functional effects of using orthobiological therapies (hyaluronic acid, platelet-rich plasma, bone marrow aspirate, nanofat, among others) in the treatment of various musculoskeletal diseases in patients routinely treated at the Proregen Medical Clinic and its affiliates. The sample will consist of adult patients (≥18 years), of both sexes, with different musculoskeletal diagnoses involving joints, tendons, ligaments, cartilage or bone, among others.

Подробное описание

Orthobiological therapies, such as hyaluronic acid, platelet-rich plasma, bone marrow aspirate concentrate, and adipose tissue derivatives, have been widely used in the management of musculoskeletal pathologies, including tendinopathies, osteoarthritis, and delayed bone consolidation. However, scientific evidence is still limited by the heterogeneity of protocols, populations, and evaluation methods. This umbrella project aims to prospectively record and analyze the clinical and functional outcomes associated with the use of these therapies in patients treated according to institutional medical indications. Participants with different osteoarticular pathologies undergoing routine orthobiological treatment at the Proregen Medical Clinic and its affiliates will be included. The central hypotheses of the study are that orthobiological therapies present measurable clinical benefits in terms of pain, function, and quality of life in various osteoarticular indications; that the safety of these approaches is adequate when performed under defined clinical criteria; and that it is possible to identify patterns of greater efficacy according to the type of orthobiological agent, the pathology, and the follow-up time. As an expected conclusion, the study aims to generate real clinical data that can serve as a basis for derivative studies, in addition to contributing to the standardization and rationalization of the use of orthobiological therapies in orthopedic practice.

Вмешательства

  • Биопрепарат PRP injection
    Obtained by centrifuging blood, it concentrates platelets and growth factors for regeneration.
  • Биопрепарат Bone Marrow Concentrate (BMAC)
    Bone marrow aspirate, rich in mesenchymal stem cells and progenitor cells for tissue repair.
  • Биопрепарат Hyaluronic Acid (Viscosupplementation)
    Used for joint lubrication and cartilage protection, very common in osteoarthritis.
  • Биопрепарат Nanofat
    It is an even more refined and liquefied form of processed fat, used primarily for high-precision tissue repair.

Первичные конечные точки

  • Pain scale [Срок оценки: From registration until six months, one year, and two years. Two years is the final follow-up period.]
  • Joint function [Срок оценки: Assessment at six months, one year, and two years. The total follow-up period is two years.]

Критерии участия

Критерии включения

  • Age 18 or older;
  • Clinical and/or radiological diagnosis of an eligible musculoskeletal condition;
  • Formal clinical indication for treatment with orthobiological agents, according to routine care;
  • Regular access to the WhatsApp application, ensuring the necessary communication for sending and receiving digital questionnaires and other study instructions;
  • Ability to understand the study and sign the Informed Consent Form.

Критерии исключения

  • Medical contraindication to the use of orthobiologics (e.g., active infection, severe hematological diseases, active cancer);
  • Recent use (≤3 months) of orthobiologic therapies in the same area to be treated;
  • Pregnant or breastfeeding women;
  • Cognitive or psychiatric diseases that prevent adequate clinical follow-up;
  • Simultaneous participation in another interventional clinical study with the same therapeutic purpose.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Публикации

  • Winkler T, Geissler S, Maleitzke T, Perka C, Duda GN, Hildebrandt A. Advanced therapies in orthopaedics. EFORT Open Rev. 2024 Sep 2;9(9):837-844. doi: 10.1530/EOR-24-0084. PMID 39222330
  • Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, Filardo G. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 2025 Mar;53(3):745-754. doi: 10.1177/03635465241246524. Epub 2025 Jan 3. PMID 39751394
  • Chu CR, Rodeo S, Bhutani N, Goodrich LR, Huard J, Irrgang J, LaPrade RF, Lattermann C, Lu Y, Mandelbaum B, Mao J, McIntyre L, Mishra A, Muschler GF, Piuzzi NS, Potter H, Spindler K, Tokish JM, Tuan R, Zaslav K, Maloney W. Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg. 2019 Jan 15;27(2):e50-e63. d PMID 30300216

Идентификаторы

NCT: NCT07434115 · 8.064.745 · Own financing

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗